Over 30% of AML patients carry FLT3 mutations, with ITD mutations occurring in the juxta-membrane domain in up to 25% of patients, which contributes to the risk of disease relapse and poor overall survival (OS) [7–9]. Here, FLT3 is linked to acute myeloid leukemia.